Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Active Controlled, Assessors-blind Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia

NCT07256912 is registered in ClinicalTrials.gov with International Agency for Research on Cancer as lead sponsor.

NCT NCT07256912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07256912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Active Controlled, Assessors-blind Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia
Lead sponsor
International Agency for Research on Cancer
Phase
Phase 4
Overall status
Active, not recruiting
Start date
June 1, 2026
Completion date
January 15, 2029
Enrollment
1,266 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer prevention, hpv vaccination, immunogenicity, quadrivalent hpv vaccine, single dose, vaccine effectiveness